Vertex reports Phase II data for pain candidate VX-150

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data from a Phase II trial in 243 patients with acute pain following bunionectomy showing that

Read the full 216 word article

User Sign In